Related Experiment Video
Updated: Sep 12, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
PDL1 Expression and Outcomes in Histiocytic Neoplasms
Matthew J Moon1, Mohammed M Milhem2, John M Rieth2
1Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Immune checkpoint inhibitors (ICIs) show promise as a first-line treatment for rare histiocytic neoplasms like histiocytic sarcoma (HS) and interdigitating dendritic cell sarcoma (IDCS). High PD-L1 expression may predict a strong response to these novel therapies.
Area of Science:
- Oncology
- Immunotherapy
- Histiocytic Neoplasms
Background:
- Histiocytic sarcoma (HS) and interdigitating dendritic cell sarcoma (IDCS) are rare, aggressive neoplasms.
- Current treatments often involve lymphoma-based chemotherapy with poor prognosis.
- Immune checkpoint inhibitors (ICIs) are increasingly used in later treatment lines.
More Related Videos
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018